Abstract:A panel of experts recently completed updating the European Guidelines for the use of Ultrasound Contrast Agents. It is due to be published in early 2008 and updates and extends the 2004 Guidelines, which covered only the liver. The new liver section, which includes the use of USCM in interstitial ablation, incorporates the recent Barcelona guidelines for management of focal lesions discovered during ultrasound surveillance in cirrhotic patients. Though focussed on SonoVue, it forms a useful framework for a general discussion of this topic. It also covers clinically established uses in the kidneys and pancreas, in abdominal trauma, in vesico-ureteric reflux and in transcranial studies. The liver section of the guidelines opens with a rationale for beginning with characterisation of focal lesions rather than their detection, as may seem logical. This points up a fundamental awkwardness of the way USCM work in the liver: the initial arterial phase is particularly useful for differentiating between various focal lesions, while the late (sinusoidal) phase is critical for determining the malignant nature of solid liver lesions. Benign lesions such as haemangiomas and focal nodular hyperplasia have a rich arterial supply and often enhance early in the arterial phase. In haemangiomas, the blood enters the lakes that constitute the abnormality at the periphery of the lesion, giving rise to peripheral nodular enhancement. From here, it percolates towards the centre of the haemangioma, usually fairly slowly, taking up to five minutes to fill completely. At this stage, the lesion disappears as it matches the intensity of the enhanced liver parenchyma, though the process is incomplete in haemangiomas that contain thrombus, usually larger lesions. Thus, delayed scanning is required to confirm that the lesion has disappeared or at least become smaller. FNHs also have an arterial supply via one or several tortuous feeding vessels. However, the flow pattern is distinctive, arriving first at the centre of the lesion and filing it in a centrifugal fashion, often forming a spoke wheel pattern. The enhancement is often intense and very rapid (the “light bulb sign”) and so the early images after arrival of the contrast are critical; the study should be recorded so that these early frames can be reviewed, if necessary in slow motion, to allow the characteristic pattern to be recognised. In the late phase, FNHs disappear as the liver enhancement matches the enhancement in the lesion. In around a quarter of cases, the central scar becomes visible in this phase as a stellate central filling defect. For both lesions, these features carry the same confidence as the equivalent CT or MR haemodynamic findings and do not require further investigation when they are typical, as is the case in around 75% of cases. Atypical cases, which amount to 5 or 10%, require further investigation. Other lesions with diagnostic haemodynamic patterns are focal fatty sparing and change as well as regenerating nodules: they have normal haemodynamics and so behave in exactly the same way as the surrounding liver, disappearing in the late phase. Hepatic adenomas seem to have a variety of patterns, but experience with them is still limited, as it is for other uncommon focal lesions such as granulomas and peliosis.

Update on MR Contrast Agents for Liver Imaging: What to Use and When

Contrast-enhanced ultrasound imaging of the liver: a review of the clinical evidence for SonoVue and Sonazoid

Gadoxetic Acid–Enhanced Liver MRI

Oral Manganese Chloride Tetrahydrate: A Novel Magnetic Resonance Liver Imaging Agent for Patients With Renal Impairment: Efficacy, Safety, and Clinical Implication

Gadolinium‐based Contrast Agents for Magnetic Resonance Cancer Imaging

Magnetic Resonance Imaging for Colorectal Cancer Metastasis to the Liver: Comparative Effectiveness Research for the Choice of Contrast Agents

Study of Clinical Application of Hepatic-Biliary Specific MR Contrast Agent(gd-Eob-dtpa) in the Diagnosis of Focal Hepatic Lesions

Advantages and Limitations of Focal Liver Lesion Assessment with Ultrasound Contrast Agents: Comments on the European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB) Guidelines

Where We Were and Where We Are

Imaging liver metastases with a new oral manganese-based contrast agent

Imaging Features of Hepatocellular Carcinoma: Quantitative and Qualitative Comparison Between MRI-Enhanced With Gd-EOB-DTPA and Gd-DTPA

Comparison of the Ability of Gadobenate Dimeglumine and Gadolinium Ethoxybenzyl Dimeglumine to Display the major Features for Noninvasively Diagnosing Hepatocellular Carcinoma According to the LI-RADS 2018v

MRI Gadolinium‐Based Contrast Media: Meeting Radiological, Clinical, and Environmental Needs

- 32S 2-1 9 th US Contrast The Diagnosis of Liver Tumours with Ultrasound Contrast

Gd-EOB-DTPA-enhanced Magnetic Resonance Imaging for Focal Liver Lesions in Chinese Patients: a Multicenter, Open-Label, Phase III Study.

Liver-targeting MRI Contrast Agent Based on Galactose Functionalized O-Carboxymethyl Chitosan

Diagnostic value of alternative techniques to gadolinium-based contrast agents in MR neuroimaging—a comprehensive overview

Gadolinium-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid conjugate of arabinogalactan as a potential liver-targeting magnetic resonance imaging contrast agent.

Is Liver-Specific Gadoxetic Acid-Enhanced Magnetic Resonance Imaging a Reliable Tool for Detection of Hepatocellular Carcinoma in Patients with Chronic Liver Disease?

Non-contrast liver MRI as an alternative to gadoxetic acid-enhanced MRI for liver metastasis from colorectal cancer

Gadoxetic acid enhanced MRI for differentiation of FNH and HCA: a single centre experience